Growth Hormone Resistance of Beta-cells in Women and People

Description

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.

Conditions

Healthy, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.

Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes

Growth Hormone Resistance of Beta-cells in Women and People

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Columbia

University of Missouri School of Medicine, Columbia, Missouri, United States, 65212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 to 45 years old
  • * hemoglobin HbA1c ≤5.6% and fasting blood glucose \<100 mg/dl
  • * body mass index ≥30.0 kg/m2 and \<45.0 kg/m2
  • * Pregnant, planning to become pregnant during the study, or breastfeeding
  • * Current diagnosis or history of type 1 or type 2 diabetes
  • * Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
  • * History of bariatric surgery
  • * Known hypothyroidism or use of thyroid medications
  • * History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
  • * Current cancer or cancer that has been in remission less than 5 years
  • * First degree relative with type 1 diabetes diagnosis
  • * Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
  • * Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
  • * Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
  • * Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Missouri-Columbia,

Bettina Mittendorfer, PhD, PRINCIPAL_INVESTIGATOR, University of Missouri-Columbia

Study Record Dates

2030-09-01